Apollomics, Inc. (NASDAQ:APLM – Get Free Report) traded down 4% during mid-day trading on Monday . The company traded as low as $9.45 and last traded at $9.50. 16,190 shares were traded during trading, a decline of 83% from the average session volume of 93,693 shares. The stock had previously closed at $9.90.
Apollomics Stock Performance
The firm has a 50-day moving average price of $8.05 and a 200-day moving average price of $10.45.
Apollomics Company Profile
Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.
Further Reading
- Five stocks we like better than Apollomics
- What to Know About Investing in Penny Stocks
- Energy Transfer: Powering Data With Dividends and Diversification
- The Risks of Owning Bonds
- Qualcomm Stock Is Coiling for a Breakout
- Why is the Ex-Dividend Date Significant to Investors?
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.
